
PSYCHIATRY GRAND ROUNDS

“UNMET NEEDS IN THE PHARMACOTHERAPY OF DEPRESSION: IS HELP REALLY ON THE WAY”

MICHAEL THASE, M.D.

*Director of Mood and Anxiety Disorders Section
Department of Psychiatry
University of Pennsylvania School of Medicine
Philadelphia, PA*

**Thursday, May 18, 2023
12:00 p.m. - 1:00 p.m.**

SNYDER AUDITORIUM AND ZOOM

THIS ACTIVITY IS DESIGNED TO HELP YOU:

- Describe the unmet needs that are not well addressed by the current state of the art for antidepressant pharmacotherapy
- State the recent developments that have led to new medications that address these problems
- Identify treatments that target glutamatergic mechanisms such as ketamine/esketamine and neurosteroids that indirectly modulate glutamatergic neurotransmission
- Describe why after 60+ years of banishment, there is renewed interest in drugs once classified as psychedelics

PHYSICIANS: Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians and adheres to the policies of the American Psychological Association regarding provision of Continuing Education.

Allegheny General Hospital designates this continuing medical education activity for a maximum of 1.0 *AMA PRA Category 1 Credits (TM)*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CE FOR PSYCHOLOGISTS: Allegheny General Hospital is approved by the American Psychological Association to offer continuing education for psychologists. Allegheny General Hospital maintains responsibility for the program and its content.

TARGET AUDIENCE: Advanced level of instruction for psychiatrists, psychologists, social workers and other medical personnel.

Faculty Disclosure: In accordance with the Accreditation Council for Continuing Medical Education (ACCME), the Association of American Medical Colleges (AAMC) Standards and the policy of Allegheny General Hospital, presenters are asked to indicate if they have any relationship which, in the context of their presentation, could be perceived as a real or apparent conflict of interest (e.g., ownership of stock, honoraria, consulting fees, etc.). Any such relationships will be disclosed to the audience and consideration will be given to possible influences of their presentation. **Dr. Thase disclosures being a consultant with Axsome, Clexio Pharma, GH Therapeutics, Janssen Pharmaceuticals, Inc., H. Lundbeck A/S, Otsuka Pharmaceuticals, Ltd., Pfizer Inc., Sage Pharmaceuticals, Seelos Pharmaceuticals, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Ltd.;** Dr. Diane Sloan (spouse) is a Sr. Vice President of Open Health which does business with many companies; has grants/research with Acadia, Alkermes, AbbieVie, AssureRX Health (now Myriad), Axsome, Intracellular, Janssen Pharmaceuticals, Inc., NIMH, Otsuka, Patient Centered Outcomes Research Institute, Takeda; royalties from American Psychiatric Press, Inc., Guilford Publications, Herald House, Kluwer-Wolters, W.W. Norton & Co, Inc. All relevant conflicts have been mitigated. Dr. Swanson (Course Director) has nothing to disclose.

The information presented in this CE offering reflects the opinion of the presenter. As with all science, there may be multiple explanations for the data and multiple reasonable conclusions.

Contact Michael Franzen, Ph.D. at (412) 330-4242 if you need information or have a concern